Background: In this study, we sought to estimate the association between oral oncology parity law adoption and anticancer medication use for patients with chronic myeloid leukemia or multiple myeloma. Methods: This was an observational study of administrative claims from 2008 to 2017. Among individuals initiating tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia or immunomodulatory drugs for multiple myeloma, we compared out-of-pocket spending, adherence, and discontinuation before and after parity among individuals in fully insured plans (subject to parity) vs self-funded plans (exempt from parity) using propensity-score weighted difference-in-differences regression models. Results: Among patients initiating TKIs (N = 2082) or...
Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chro...
Background: Tyrosine Kinase Inhibitors (TKIs) are drugs of choice for Chronic Myeloid Leukemia (CML)...
PURPOSE: Existing studies evaluating patient adherence to oral targeted therapies such as tyrosine k...
IMPORTANCE Oral anticancer medications are increasingly important but costly treatment options for p...
There is substantial concern surrounding affordability of orally administered anticancer therapies, ...
Untreated chronic phase chronic myeloid leukemia (CML) will eventually progress to advanced phase in...
Background—Tyrosine kinase inhibitors (TKIs) improve survival of chronic myeloid leukemia (CML) pati...
AbstractOver the last decade, there has been increased development and use of oral anticancer medica...
Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherenc...
INTRODUCTION: Tyrosine kinase inhibitors (TKI) have been demonstrated to prolong survival in patient...
Thesis (Ph.D.)--University of Washington, 2022Gleevec is a specialty drug that revolutionized the tr...
Background: Chronic myelogenous leukemia (CML) accounts for 15% of all adult leukemias. Oral tyrosin...
Purpose: Access to cutting edge treatments is important for patients who are battling cancer in the ...
Treatment with tyrosine kinase inhibitors (TKIs) has dramatically improved the prognosis for patient...
Purpose: Poor adherence to tyrosine kinase inhibitors (TKIs) could compromise the control of chronic...
Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chro...
Background: Tyrosine Kinase Inhibitors (TKIs) are drugs of choice for Chronic Myeloid Leukemia (CML)...
PURPOSE: Existing studies evaluating patient adherence to oral targeted therapies such as tyrosine k...
IMPORTANCE Oral anticancer medications are increasingly important but costly treatment options for p...
There is substantial concern surrounding affordability of orally administered anticancer therapies, ...
Untreated chronic phase chronic myeloid leukemia (CML) will eventually progress to advanced phase in...
Background—Tyrosine kinase inhibitors (TKIs) improve survival of chronic myeloid leukemia (CML) pati...
AbstractOver the last decade, there has been increased development and use of oral anticancer medica...
Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherenc...
INTRODUCTION: Tyrosine kinase inhibitors (TKI) have been demonstrated to prolong survival in patient...
Thesis (Ph.D.)--University of Washington, 2022Gleevec is a specialty drug that revolutionized the tr...
Background: Chronic myelogenous leukemia (CML) accounts for 15% of all adult leukemias. Oral tyrosin...
Purpose: Access to cutting edge treatments is important for patients who are battling cancer in the ...
Treatment with tyrosine kinase inhibitors (TKIs) has dramatically improved the prognosis for patient...
Purpose: Poor adherence to tyrosine kinase inhibitors (TKIs) could compromise the control of chronic...
Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chro...
Background: Tyrosine Kinase Inhibitors (TKIs) are drugs of choice for Chronic Myeloid Leukemia (CML)...
PURPOSE: Existing studies evaluating patient adherence to oral targeted therapies such as tyrosine k...